Caribou Biosciences Inc (CRBU) Beta Value: Understanding the Market Risk

The 36-month beta value for CRBU is also noteworthy at 2.47. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for CRBU is 79.39M, and at present, short sellers hold a 12.69% of that float. The average trading volume of CRBU on April 02, 2024 was 1.61M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

CRBU) stock’s latest price update

Caribou Biosciences Inc (NASDAQ: CRBU) has seen a decline in its stock price by -4.85 in relation to its previous close of 5.05. However, the company has experienced a -9.17% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-14 that Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CRBU’s Market Performance

Caribou Biosciences Inc (CRBU) has seen a -9.17% fall in stock performance for the week, with a -38.32% decline in the past month and a -16.14% plunge in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are at 8.11% for CRBU. The simple moving average for the past 20 days is -18.47% for CRBU’s stock, with a -15.29% simple moving average for the past 200 days.

Analysts’ Opinion of CRBU

Evercore ISI, on the other hand, stated in their research note that they expect to see CRBU reach a price target of $13. The rating they have provided for CRBU stocks is “Outperform” according to the report published on October 31st, 2023.

Truist gave a rating of “Buy” to CRBU, setting the target price at $23 in the report published on July 11th of the previous year.

CRBU Trading at -24.07% from the 50-Day Moving Average

After a stumble in the market that brought CRBU to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.06% of loss for the given period.

Volatility was left at 8.11%, however, over the last 30 days, the volatility rate increased by 5.20%, as shares sank -35.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.76% lower at present.

During the last 5 trading sessions, CRBU fell by -8.79%, which changed the moving average for the period of 200-days by +4.21% in comparison to the 20-day moving average, which settled at $5.76. In addition, Caribou Biosciences Inc saw -16.14% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for CRBU

Current profitability levels for the company are sitting at:

  • -3.37 for the present operating margin
  • 0.82 for the gross margin

The net margin for Caribou Biosciences Inc stands at -2.87. The total capital return value is set at -0.28. Equity return is now at value -30.50, with -24.74 for asset returns.

Based on Caribou Biosciences Inc (CRBU), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -3.39. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 37.78.

Currently, EBITDA for the company is -112.53 million with net debt to EBITDA at 0.21. When we switch over and look at the enterprise to sales, we see a ratio of 12.04. The receivables turnover for the company is 8.93for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.97.

Conclusion

In summary, Caribou Biosciences Inc (CRBU) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts